Kymera Therapeutics (KYMR) Investor Presentation - Slideshow

Company Overview - Kymera is a fully integrated protein degrader medicine company focused on immune inflammation and oncology [6] - The company has a well-positioned cash balance of $647 million as of June 30, 2021 [6] Pipeline and Programs - Kymera expects 2 additional INDs and clinical initiations by the end of 2021 [6] - KT-474 is an IRAK4 degrader targeting atopic dermatitis, hidradenitis suppurativa, rheumatoid arthritis, and others, with proof-of-biology expected in Q4 2021 [7] - KT-413 is an IRAKIMiD (IRAK4, Ikaros, Aiolos) targeting MYD88 MT DLBCL, with Phase 1 initiation expected in 2H 2021 [7, 38] - KT-333 is a STAT3 degrader targeting liquid & solid tumors, with IND/Phase 1 initiation expected in 4Q 2021 [7, 52] KT-474 Clinical Trial Results - In a Phase 1 healthy volunteer SAD trial, a single 300 mg dose of KT-474 achieved a median IRAK4 reduction of 90% (p<00001 vs placebo) with a maximum reduction of 94% at 48 hours [32] - IRAK4 reduction lasted for at least 6 days post-dose in all dose groups [29] - The Phase 1 trial includes SAD and MAD portions in healthy volunteers and a patient cohort with atopic dermatitis and hidradenitis suppurativa [22]